ŌURA Brings Menopause Impact Scale into Clinical Care through Expanding Partner Network

The digital health landscape is undergoing a significant transformation as consumer wearable technology increasingly intersects with formal medical care. Today, smart ring manufacturer Oura has announced a major expansion of its proprietary Menopause Impact Scale (MIS). By integrating the MIS into an ecosystem of ten prominent healthcare partners spanning specialty menopause care, primary care, telehealth, and hormone tracking platforms, Oura aims to establish a universal framework for tracking the multi-year health transition of menopause.

The initial rollout includes strategic integrations with Alloy Health, Oova, Xella, Pomelo, and Wisp, with subsequent platform integrations for Maven, Mira, Hertility, Gennev, and Tia scheduled to launch later this year. This move transitions the MIS from a localized tool residing exclusively within the Oura App into a portable, standardized metric utilized across diverse real-world clinical and health workflows. By bridging the gap between patient-reported lived experiences and continuous physiological metrics, the initiative seeks to eliminate the fragmentation that has historically plagued women’s healthcare, offering a cohesive methodology for patients and their multidisciplinary care teams.

The Evolution of Menopause Care and the Genesis of the MIS

For generations, the medical community’s approach to menopause has been criticized as narrow, episodic, and overly reliant on point-in-time clinical conversations. Historically, patients navigating midlife health transitions were forced to repeatedly recount transient symptoms to various providers—from primary care physicians to gynecologists and endocrinologists—without the benefit of a longitudinal record. This fragmented diagnostic journey often reduced complex, multi-system physiological shifts to isolated medical snapshots.

Recognizing this systemic inefficiency, Oura developed the Menopause Impact Scale to provide a consistent, standardized mechanism for tracking how menopause affects daily functioning and overall quality of life over extended periods. The development of the scale was anchored in rigorous scientific methodology. Oura’s internal science and clinical teams conducted extensive reviews of existing medical literature and evaluated the assessment tool across a cohort of nearly 3,000 women.

Unlike traditional evaluation methods that focus solely on discrete physical complaints—such as hot flashes—the MIS assesses the broader, systemic impact of hormonal fluctuations. It comprehensively captures how these shifts interfere with sleep quality, cognitive performance (often described as brain fog), emotional well-being, self-perception, sexual health, and daily productivity. By converting these nuanced experiences into actionable data, the tool enables clinicians to view menopause not as a momentary medical event, but as a dynamic, multi-year physiological transition requiring continuous, connected management.

An Expanding Ecosystem of Ten Strategic Healthcare Partners

The integration of the MIS into ten distinct healthcare organizations represents a diverse cross-section of modern medical delivery models. These partners encompass virtual-first menopause clinics, comprehensive women’s health platforms, primary care networks, and specialized hormone and biomarker tracking services. Each organization incorporates the MIS at critical touchpoints along the patient journey, ensuring that subjective symptom reporting is systematically paired with objective clinical oversight.

The participating partners represent a broad spectrum of clinical expertise and technological infrastructure:

• Alloy Health: A leading telehealth platform specializing in midlife women’s health and personalized hormone replacement therapy.
• Oova: A hormone tracking and biomarker platform providing quantitative insights into ovarian reserve and hormonal fluctuations.
• Xella: An emerging digital health platform focused on customized wellness and longevity strategies for women.
• Pomelo Care: A virtual-first maternal and women’s health medical practice designed to support comprehensive care coordination.
• Wisp: A nationwide telehealth provider offering accessible, stigma-free sexual and reproductive health services, including menopause support.
• Maven Clinic: The world’s largest virtual clinic for women’s and family health, providing integrated employer and consumer care.
• Mira: A provider of quantitative, lab-grade hormone tracking monitors for home use.
• Hertility Health: A reproductive health and science company offering at-home hormone testing and clinical diagnostics.
• Gennev: A dedicated online clinic for menopausal care, backed by the Unified Women’s Health clinical network.
• Tia: An integrated healthcare platform designed specifically for women, blending virtual care, brick-and-mortar clinics, and continuous digital tracking.

This diverse network creates a unified measurement layer. When a patient transitions from a home hormone-tracking app to a virtual menopause clinic, or from a primary care provider to a specialized endocrinologist, their MIS data travels with them. This continuity provides every provider in the care continuum with an identical starting point, drastically reducing administrative friction and improving diagnostic accuracy.

Expert Perspectives from Clinical Leaders

Medical directors and chief medical officers across Oura’s partner network have emphasized the profound clinical value of embedding standardized patient-reported outcomes into routine workflows.

Dr. Elizabeth Cherot, chief medical officer at Unified Women’s Health—the parent company of Gennev and the largest OBGYN clinical network in the United States—highlighted the psychological and physiological breadth of the menopausal transition. “Disrupted sleep, brain fog, shifts in mood, lower energy,” Dr. Cherot noted. “Women experience the signs and symptoms of this transition in their day-to-day life long before any of it comes up in an exam room. What’s great about the MIS is that it brings her lived experience into the clinical conversation. By integrating evidence-based clinical care with data from her daily life, we’re giving our clinicians at Gennev a better way to track and support her needs as they evolve.”

Echoing these sentiments, Dr. Sharon Malone, chief medical advisor at Alloy Health, pointed to the extreme variability of the menopausal experience among individual patients. “As a physician, one of the most important things I’ve learned is that no two menopause experiences are alike,” stated Dr. Malone. “It’s not enough to know what symptoms a woman is having. We need to understand how these symptoms are affecting the quality of a woman’s life. At Alloy, that individual experience is at the heart of how we think about menopause care. There is no one size fits all. The Menopause Impact Scale provides another meaningful layer of context that a woman and her doctor can bring to the conversation. The more we know, the better we are able to help women make informed decisions not just about symptom relief, but also about their long-term health.”

Methodological Rigor and Quantitative Validation

The technical architecture of the Menopause Impact Scale is built upon rigorous psychometric validation. Developed to quantify the impact of menopause on quality of life and daily functioning, the instrument evaluates 22 distinct symptoms categorized across seven core domains. When these patient-reported metrics are cross-referenced with continuous physiological data streams generated by Oura rings—such as autonomic nervous system recovery, skin temperature trends, resting heart rate, sleep architecture, and metabolic markers—clinicians gain a comprehensive dual-perspective view of patient health. This synthesis connects subjective daily experiences with objective physiological patterns over extended timeframes.

Before deploying the scale to the broader public, Oura’s research teams subjected the digital-first instrument to extensive empirical testing. The validation study evaluated the scale with more than 2,900 participants ranging in age from 21 to 85. Researchers utilized modern psychometric evaluation methods, comparing the MIS against established clinical measures of menopausal distress to ensure high reliability and construct validity. Following this exhaustive evaluation, the complete validation manuscript was submitted to a peer-reviewed medical journal for formal academic publication.

The real-world uptake of the tool has been rapid. Since its initial launch in May, more than 600,000 Oura members have completed the MIS questionnaire, resulting in a cumulative total of over 880,000 individual completions. Geographically, adoption reflects a broad international footprint: approximately 62% of respondents reside within the United States, while the remaining 38% are distributed globally. This substantial volume of engagement demonstrates not only a high demand among consumers for specialized menopause tracking tools, but also the repeated utilization required to generate meaningful longitudinal health data.

A Broader Foundation in Women’s Health Research

The expansion of the MIS is not an isolated initiative; rather, it represents the latest milestone in Oura’s sustained, multi-year investment in women’s health research and product development. This trajectory includes the October 2024 release of the industry’s first-ever Perimenopause Report. That landmark study analyzed aggregate, de-identified biometric data from more than 100,000 female members categorized across early perimenopause, late perimenopause, and early postmenopause. The findings offered unprecedented visibility into how natural hormonal transitions during midlife systematically alter sleep patterns, cardiovascular metrics, and stress resilience.

Oura’s broader scientific credibility in reproductive health is further underscored by published, peer-reviewed clinical studies. In a rigorous validation study involving more than 1,000 ovulatory cycles, the company’s physiology-based algorithmic approach successfully detected 96.4% of ovulations with a mean margin of error of just 1.26 days. This performance significantly outperformed traditional calendar-based tracking methods, proving particularly effective among cohorts characterized by irregular menstrual cycles.

Additional collaborative research initiatives with leading academic institutions have utilized Oura sensor data to identify micro-fluctuations in basal body temperature immediately following conception. Furthermore, published studies in digital medicine journals have demonstrated the wearable device’s capacity to predict pregnancy delivery timing—differentiating between preterm and post-term deliveries—with an accuracy rate of 71%. Together, this accumulating body of validated research establishes a robust scientific foundation for translating continuous sensor data into clinically actionable insights across the entire spectrum of women’s health.

Implications for the Future of Digital Health and Clinical Practice

The integration of consumer wearable data into formalized clinical workflows through the expanded MIS ecosystem signals a broader paradigm shift in modern medicine. For decades, consumer health devices and clinical electronic health records (EHRs) operated in parallel, non-communicating silos. Physicians frequently treated self-tracked consumer data with skepticism, while patients struggled to convey the nuances of their daily wearable analytics during brief, ten-minute clinical consultations.

By establishing a standardized, validated measurement layer that spans both consumer applications and professional telehealth platforms, Oura and its ten new partners are attempting to construct a unified bridge across this divide. The implications of this integration extend beyond individual symptom management. A standardized longitudinal dataset of this scale holds immense potential for advancing clinical outcomes research, refining medical decision-support systems, and designing targeted interventions for midlife health transitions.

As healthcare delivery continues its rapid migration toward hybrid and virtual-first models, tools that synthesize patient-reported qualitative experiences with continuous quantitative telemetry will likely become the gold standard. By embedding the Menopause Impact Scale directly into the daily operational software of trusted providers like Alloy Health, Maven, Gennev, and Tia, Oura is positioning continuous biometric monitoring as an essential, accepted component of mainstream gynecological and primary care. The rollout of these remaining integrations throughout the remainder of the year will serve as a critical test case for the scalability and clinical utility of wearable-informed medical care.